Clinical Efficacy and Safety of Apatinib Combined with Paclitaxel and Carboplatin in the Treatment of Advanced Esophageal Cancer
Objective To investigate the clinical efficacy and safety of apatinib combined with paclitaxel and carboplatin in the treatment of advanced esophageal cancer.Methods 100 patients with advanced esophageal cancer admitted to the Hematology Department of Jiyang District People's Hospital from February 2021 to June 2023 were selected as the study objects,and were divided into a control group and an observation group according to random number table method,with 50 cases in each group.The control group was treated with paclitaxel and carboplatin,and the observation group was treated with apatinib on the basis of the control group.The clinical efficacy,tumor marker levels,quality of life and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 90.00%,which was higher than that of the control group(74.00%),the difference was statistically significant(P＜0.05).After treatment,the levels of carcinoembryonic antigen,carbohydrate antigen-199 and carbohydrate antigen-72-4 in the observation group were(5.48±0.92)ng/mL,(30.68±3.03)U/mL and(6.81±0.80)U/mL,respectively.It was lower than(6.71±1.06)ng/mL,(36.08±3.40)U/mL and(8.04±0.96)U/mL in control group,and the differences between groups were statistically significant(P＜0.05).The scores of physical function,cognitive function,role function,emotional function and social function in the observation group were(72.56±2.97)points,(70.03±2.42)points,(71.05±3.68)points,(72.06±2.98)points and(65.34±2.80)points,respectively,were higher than the control group(67.64±2.82)points,(65.68±2.76)points,(64.29±3.56)points,(66.09±2.70)points,(60.09±2.62)points,the differences between groups were statistically significant(P＜0.05).The total incidence of adverse reactions in the observation group was 10.00%,lower than that in the control group(28.00%),and the difference was statistically significant(P＜0.05).Conclusion Apatinib combined with paclitaxel and carboplatin is effective in the treatment of advanced esophageal cancer,which can reduce tumor marker levels,improve quality of life,reduce adverse reactions,and is safe and reliable.
NETL
NSTL
万方数据
